Evidence map›Paper›PMID 31745706›Full record

ArticleJournal of neuro-oncology2020

Brachytherapy with surgical resection as salvage treatment for recurrent high-grade meningiomas: a matched cohort study.

Michael A Mooney, Wenya Linda Bi, Jonathan M Cantalino, Kyle C Wu, Thomas C Harris, Lucas L Possatti, Parikshit Juvekar, Liangge Hsu, Ian F Dunn, Ossama Al-Mefty and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Brachytherapy for central nervous system tumors.Journal of neuro-oncology · 2022
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Michael A MooneyDepartment of Neurosurgery, Barrow Neurological Institute, 350 W. Thomas Rd, Phoenix, AZ, USA. michael.mooney@bnaneuro.net.ORCID http://orcid.org/0000-0001-5428-051X
Wenya Linda BiDepartment of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Jonathan M CantalinoDepartment of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA.
Kyle C WuDepartment of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Thomas C HarrisDepartment of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA.
Lucas L PossattiDepartment of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Parikshit JuvekarDepartment of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Liangge HsuDepartment of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
Ian F DunnDepartment of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Ossama Al-MeftyDepartment of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.
Phillip M DevlinDepartment of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA.
Brigham and Women's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate surgical resection with brachytherapy placement as a salvage treatment in patients with recurrent high-grade meningioma who exhausted prior external beam treatment options.

methodsSingle-center retrospective review of our institutional experience of brachytherapy implantation from 2012 to 2018. The primary outcome of the study was progression free survival (PFS). Secondary outcomes included overall survival (OS) and complications. A matched cohort of patients not treated with brachytherapy over the same time period was evaluated as a control group. All patients had received prior radiation treatment and underwent planned gross total resection (GTR) surgery.

resultsA total of 27 cases were evaluated. Compared with prior treatment, brachytherapy implantation demonstrated a statistically significant improvement in tumor control [HR 0.316 (0.101 - 0.991), p = 0.034]. PFS-6 and PFS-12 were 92.3% and 84.6%, respectively. Compared with the matched control cohort, brachytherapy treatment demonstrated improved PFS [HR 0.310 (0.103 - 0.933), p = 0.030]. Overall survival was not statistically significantly different between groups [HR 0.381 (0.073 - 1.982), p = 0.227]. Overall postoperative complications were comparable between groups, although there was a higher incidence of radiation necrosis in the brachytherapy cohort.

conclusionBrachytherapy with planned GTR improved PFS in recurrent high-grade meningioma patients who exhausted prior external beam radiation treatment options. Future improvement of brachytherapy dose delivery methods and techniques may continue to prolong control rates and improve outcomes for this challenging group of patients.

Indexed as

Salvage TherapyAdultAgedAged, 80 and overBrachytherapyCombined Modality TherapyFemaleFollow-Up StudiesHumansMaleMeningeal NeoplasmsMeningiomaMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeurosurgeryAnaplasticAtypicalBrachytherapyMeningiomaRadiationRecurrence

Identifiers

PMID31745706
OpenAlexW2990262482

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.